Radical surgery is the standard of care for fit stage I non-small cell lung cancer (NSCLC)
patients. Adjuvant treatment should be offered only as part of an investigation trial. Stage II …

The American Society of Clinical Oncology (ASCO) previously published evidencebased
guidelines for the treatment of unresectable non–small-cell lung cancer (NSCLC)[1]. ASCO …

PURPOSE: This randomized trial was designed to determine whether paclitaxel plus
carboplatin (PC) offered a survival advantage over vinorelbine plus cisplatin (VC) for …

PURPOSE: To evaluate whether two commonly used newer platinum-based regimens offer
any advantage over vinorelbine-cisplatin (reference regimen) in response rate for patients …

Purpose: Overexpression of the excision repair cross-complementing 1 (ERCC1) gene,
which is crucial in the repair of cisplatin (CDDP)-DNA adducts, is reported to negatively …

Gemcitabine, a pyrimidine nucleoside antimetabolite, is one of the most promising new
cytotoxic agents. The drug has shown activity in a variety of solid tumors, and has been …

PURPOSE: The primary objective of this randomized phase III study was to show significant
difference in median time to progression (TTP) in patients with advanced NSCLC treated …

Background: Brain metastases are a common occurrence in patients with non-small-cell
lung cancer (NSCLC). Whole-brain radiotherapy (WBRT) is the standard therapy; more …

PURPOSE: To compare four cycles of therapy versus continuous therapy to determine the
optimal duration of chemotherapy in advanced non–small-cell lung cancer (NSCLC) …

Deterioration in exercise tolerance and impairment in quality of life (QoL) are common
consequences of lobectomy. This study evaluates additional exercise and strength training …